Comparative responses to 17 different antidepressants in major depressive disorder: Results from a 2‐year long‐term nation‐wide population‐based study emulating a randomized trial
Acta Psychiatrica Scandinavica · 2024
DOI: 10.1111/acps.13673 ↗At a glance
Vergleichsstudie in Acta Psychiatrica Scandinavica, 2024. Written by Lars Vedel Kessing and 4 co-authors. Institution: Copenhagen Affective disorder Research Center (CADIC), Psychiatric Center Copenhagen, Copenhagen, Denmark. Major MEDLINE topics: Major Depressive Disorder. Cited 10 times so far (Crossref); 31 references. Funded by: Lundbeck Foundation.
Abstract (original language)
Background
Long‐term studies comparing nonresponse to antidepressants for major depressive disorder (MDD) are lacking.
Aims
To present systematic population‐based nation‐wide register data on comparative 2‐year non‐response within six antidepressant drug classes and 17 different antidepressants in patients with MDD.
Method
The study included all 106,920 patients in Denmark with a first main index diagnosis of MDD at a psychiatric hospital inpatient or outpatient contact and who subsequently had a purchase of an antidepressant in the period from 1995 to 2018. Non‐response to first antidepressant within a 2‐year study period was defined as switch to or add‐on of another antidepressant, antipsychotic medication, lithium, or hospitalization. Analyses emulated a targeted trial in populations standardized according to age, sex, socioeconomic status, and comorbidity with psychiatric and physical disorders.
Results
Compared with sertraline, there was no difference for citalopram (RR: 1.00 [95% CI: 0.98–1.02]) but fluoxetine (1.13 [95% CI: 1.10–1.17]), paroxetine (1.06 [95% CI: 1.01–1.10]) and escitalopram (1.22 [95% CI: 1.18–1.25]) were associated with higher risk ratio of non‐responses. Within selective noradrenaline reuptake inhibitors, sertraline outperformed reboxetine; within serotonin‐norepinephrine reuptake inhibitors, venlafaxine outperformed duloxetine; within noradrenergic and specific serotonergic antidepressants , mirtazapine outperformed mianserin and within the class of other antidepressants, sertraline outperformed agomelatine and vortioxetine. Within tricyclic antidepressants, compared to amitriptyline, nortriptyline, dosulepin, and clomipramine had higher non‐response, whereas there was no difference for imipramine.
Conclusions
These analyses emulating a randomized trial of “real world” observational register‐based data show that 2‐year long‐term non‐responses to some antidepressants within six different drug classes are increased over others.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Copenhagen Affective disorder Research Center (CADIC), Psychiatric Center Copenhagen, Copenhagen, Denmark.
- Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
- Department of Biostatistics, University of Copenhagen, Copenhagen, Denmark.
ORCID profiles: Lars Vedel Kessing
Funding
- Lundbeck Foundation
Cite
APA
Kessing, L. V., Ziersen, S. C., Andersen, F. M., Gerds, T., & Budtz-Jørgensen, E. (2024). Comparative responses to 17 different antidepressants in major depressive disorder: Results from a 2‐year long‐term nation‐wide population‐based study emulating a randomized trial. Acta Psychiatrica Scandinavica. https://doi.org/10.1111/acps.13673
Vancouver
Kessing LV, Ziersen SC, Andersen FM, Gerds T, Budtz-Jørgensen E. Comparative responses to 17 different antidepressants in major depressive disorder: Results from a 2‐year long‐term nation‐wide population‐based study emulating a randomized trial. Acta Psychiatrica Scandinavica. 2024. doi:10.1111/acps.13673
BibTeX
@article{Kessing2024,
author = {Kessing, Lars Vedel and Ziersen, Simon Christoffer and Andersen, Frederik Mølkjær and Gerds, Thomas and Budtz-Jørgensen, Esben},
title = {Comparative responses to 17 different antidepressants in major depressive disorder: Results from a 2‐year long‐term nation‐wide population‐based study emulating a randomized trial},
journal = {Acta Psychiatrica Scandinavica},
year = {2024},
doi = {10.1111/acps.13673}
}
EUVIMED